|
Mechanism5-HT receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Unknown statusPhase 1/2 Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study
The purpose of this study is to determine the efficacy of DD-25, a new topical drug, on plaque Psoriasis Vulgaris.
The study will include subjects at plaque stage from 5-20% body area involvement. A total of 30 subjects will be treated with cream application on affected areas twice daily for three weeks.The efficacy of the preparation will be documented by PASI score, Global physician assessment and photos.
100 Clinical Results associated with Fortuderm Ltd.
0 Patents (Medical) associated with Fortuderm Ltd.
100 Deals associated with Fortuderm Ltd.
100 Translational Medicine associated with Fortuderm Ltd.